FDA Inspection
3D Imaging Drug Design and Development3D Imaging Drug Design and Development – FDA Inspection, Jan 31, 2024
Record Details
This FDA Inspection record concerns 3D Imaging Drug Design and Development, with an inspection on January 31, 2024, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · b62a272a-50d6-4a9e-99be-3d3008f0eb1d
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1228168
- FDA center
- Human Drugs
- Project area
- Bioresearch Monitoring
FDA Citations
1- 21 CFR 314.80(b)Failure to develop written procedures
Full citation text and observation details available on the Dashboard.
Other FDA inspections of 3D Imaging Drug Design and Development
3| Date | Classification | Office | Project area |
|---|---|---|---|
| June 13, 2025 | OAI | Dallas District Office | Drug Quality Assurance |
| January 18, 2019 | VAI | Dallas District Office | Generic Drug Evaluation |
| April 20, 2017 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for 3D Imaging Drug Design and Development
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.